Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14719073 | 0.92 | GRIN2B (0.50) | KMT2AMEN1GRIN2BGRIN2COPRD1 | |
| SCHEMBL14085917 | 0.91 | HDAC1 (0.45) | KMT2AMEN1GRIN2BGRIN2COPRD1 | |
| SCHEMBL21225697 | 0.87 | GRIN2B (0.42) | KMT2AMEN1GRIN2BGRIN2COPRD1 | |
| SCHEMBL21224551 | 0.84 | GRIN2B (0.48) | GRIN2BGRIN2COPRD1OPRK1PDE4A | |
| SCHEMBL14282652 | 0.82 | GRIN2B (0.50) | GRIN2BGRIN2CNPC1L1 | |
| SCHEMBL22087518 | 0.81 | GRIN2B (0.48) | GRIN2BGRIN2CHDAC1HDAC6HDAC8 | |
| SCHEMBL14016362 | 0.81 | MEN1 (0.50) | KMT2AMEN1 | |
| SCHEMBL29557107 | 0.79 | GRIN2B (0.51) | GRIN2BGRIN2CALDH1A1PDE4APDE4B | |
| SCHEMBL5134060 | 0.79 | GRIN2B (0.49) | GRIN2BGRIN2CNPC1L1 | |
| SCHEMBL25852386 | 0.78 | GRIN2B (0.51) | GRIN2BGRIN2CPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3858349-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2021-08-04 | — | — | EP | disclosed |
| EP-3181570-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco Inc. (JP) | 2017-06-21 | — | — | EP | disclosed |
| EP-2460806-B1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | JAPAN TOBACCO INC (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8609647-B2 | Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof | JAPAN TOBACCO INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| EP-2460806-A1 | NITROGEN-CONTAINING SPIRO-RING COMPOUND AND MEDICINAL USE OF SAME | Japan Tobacco, Inc. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | KMT2A 3312/4885MEN1 259/4885GRIN2B 2949/4885 |
| US-20230023377-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NPR1 | KMT2A 3608/4885MEN1 218/4885GRIN2B 3350/4885 |
| US-20140187534-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | KMT2A 3312/4885MEN1 259/4885GRIN2B 2949/4885 |
| US-20240150367-A1 | NITROGEN-CONTAINING SPIRO CYCLIC COMPOUNDS AND PHARMACEUTICAL USE THEREOF | REN, PKD1, NPR1 | KMT2A 3544/4885MEN1 204/4885GRIN2B 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.